Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | IDH2 | P48735 | 2/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 2/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3023084 | 0.88 | CDK2 (0.50) | FLT3CDK2CCNE1PIM1IDH2 | |
| SCHEMBL3018859 | 0.88 | CDK2 (0.50) | FLT3CDK2CCNE1PIM1IDH2 | |
| SCHEMBL3023189 | 0.84 | CDK2 (0.52) | FLT3CDK2CCNE1MAPKAPK2IRAK4 | |
| SCHEMBL5468752 | 0.84 | MAPKAPK2 (0.53) | FLT3CDK2CCNE1MAPKAPK2 | |
| SCHEMBL3022676 | 0.82 | CDK2 (0.56) | FLT3CDK2CCNE1MAPKAPK2 | |
| SCHEMBL3017898 | 0.81 | CDK2 (0.51) | FLT3CDK2CCNE1MAPKAPK2IRAK4 | |
| SCHEMBL3025821 | 0.81 | FLT3 (0.45) | FLT3CDK2CCNE1PIM1IDH2 | |
| SCHEMBL3012108 | 0.80 | FLT3 (0.46) | FLT3CDK2CCNE1MAPKAPK2IRAK4 | |
| SCHEMBL9004584 | 0.79 | BTK (0.54) | FLT3CDK2CCNE1MAPKAPK2CHEK1 | |
| SCHEMBL3023353 | 0.79 | CDK2 (0.53) | FLT3CDK2CCNE1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | FLT3 345/4885CDK2 40/4885CCNE1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.